Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more
Pure Biologics Spólka Akcyjna (PUR) - Total Liabilities
Latest total liabilities as of September 2025: zł20.72 Million PLN
Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has total liabilities worth zł20.72 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pure Biologics Spólka Akcyjna - Total Liabilities Trend (2016–2024)
This chart illustrates how Pure Biologics Spólka Akcyjna's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pure Biologics Spólka Akcyjna Competitors by Total Liabilities
The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LTI0
F:LTI0
|
Germany | €25.79 Million |
|
Sulliden Minerals SA
TO:SMC
|
Canada | CA$2.72 Million |
|
Hayasa Metals Inc.
V:HAY
|
Canada | CA$634.34K |
|
GMP Property SOCIMI SA
MC:YGMP
|
Spain | €1.02 Billion |
|
Addentax Group Corp
NASDAQ:ATXG
|
USA | $6.62 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Pure Biologics Spólka Akcyjna's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 15.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pure Biologics Spólka Akcyjna's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pure Biologics Spólka Akcyjna (2016–2024)
The table below shows the annual total liabilities of Pure Biologics Spólka Akcyjna from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł15.46 Million | -25.84% |
| 2023-12-31 | zł20.84 Million | +41.69% |
| 2022-12-31 | zł14.71 Million | +90.97% |
| 2021-12-31 | zł7.70 Million | -64.71% |
| 2020-12-31 | zł21.83 Million | +49.80% |
| 2019-12-31 | zł14.57 Million | +234.41% |
| 2018-12-31 | zł4.36 Million | +290.25% |
| 2017-12-31 | zł1.12 Million | +74.43% |
| 2016-12-31 | zł640.12K | -- |